Nomisma Healthcare is the pioneer in the manufacturing & supplying of Bioabsorbable polymers in India & across the globe to
make the cost-effective end product for the next generation of medicine & pharmacology.
Welcome to the world of Next Generation Medicines.
Now a days, the scenario is of Biodegradable polymers, which have inherent potential with minimal side effects, rendering its usage in the field of medicine & pharmacology to relieve and recover patients from complex diseases effectively and efficiently when compared with the dosage form having no biopolymers in its composition of the same category of a drug product.
Cost-effective PLGA and PLA nanoparticles for Drug formulation as nanomedicine and biodegradable orthopedic implants
Since its commencement, Nomisma Healthcare has acquired abilities and specialization with business backing to give its customers precise data and outstanding items as regards. With highly qualified experts, the Nomisma group has a brilliant conception of the complexities of the market and has firm associations with key collaborators to take the organization forward.
At Nomisma Healthcare, PLGA i.e. Poly (lactic-co-glycolic) acid and PLA i.e. Polylactic acid Nanoparticles based polymers, are manufactured at our ISO 9001-2015 certified facility, meeting the desired quality standards for its efficient & successful use.
We offer in both, the small and large scale quantities of biopolymers. We provide the best quality biodegradable polymers to become trustable global polymer suppliers, meeting the products with international pharmaceutical quality standards.
Polylactic acid and Polylactic co Glycolic acids, also referred to as PLA and PLGA, are produced by ring-opening polymerization of corresponding lactide and glycolide monomers with a specific catalyst that is nontoxic. Their degradation properties and a long history of use in human products make PLGA, a desirable product for drug delivery, medical device, and combination products. The Nomisma Healthcare brand has been a reliable and proven source of these products in India and across the globe via a new technology approach at a reasonable price.
At Nomisma healthcare, the range of PLGA incorporates monomer compositions of Lactic acid to glycolic acid like 50:50, 75:25, 85:15, 45:55, etc. in Poly (lactic-co-glycolic) acid. These products are offered in a range of molecular weights and acid, hydroxyl, and ester end groups.
It would be ideal for different prerequisites of PLGAs if you don't hesitate to contact/write to us. Also, our skilled research team can do the custom synthesis as per the customer’s demands by applicable modifications in polymer synthesis.
|Key features||Nomisma Healthcare Brand||Global Brand||Merits of Nomisma Healthcare Brand|
|Metal content||Nontoxic Metals are used for the polymerization reaction. These metals fall under the class-IV category and it requires less tight control for their content in polymer.||Toxic Metals are used for the polymerization reaction. These metals fall under the class-III category and it requires very tight control for its content in polymer.||Polymer brand with nontoxic metal content is more preferred for the orthopedic implant as well as for drug-loaded with polymers for short- & long-term use.|
|Solvents||Class –III category solvents are used for processing steps during polymer isolation.||Class–II category solvents together with Class-III are used for processing steps during polymer isolation.||Class-III solvents are less hazardous and more preferred when compared with Class-II solvents.|
|Product Potency||The potency test is reported by using the Q-NMR technique with a specified and tight limit.||The potency test is either not reported is not considered in release analysis.||A more reliable technique is used for the potency test with stringent control.|
|Product stability||The non-lyophilization technique is used for product isolation which renders the product with more shelf life over a period of time.||Generally, the lyophilization technique is used for product isolation which renders the product with less shelf life over a period of time.||The product has an inherent stable character.|
|Product delivery||Unique technology delivers higher production which in turn helps to meet product delivery.||Restricted batch size leading to lesser production which in turn requires a wide timeline for product delivery.||In-time delivery of the product.|
|Product cost||A unique process with a higher production capacity renders it less costly.||Restricted batch size, use of costlier metal reagents, and lyophilization technique, all together make the product costly.||Polymer product with Quality & cheaper price makes the end product/project more feasible and less costly.|
The Characterization of Polymer, to be used in complex drug formulation, is a key requirement. To fulfill this requirement considering the regulatory aspects, at Nomisma Healthcare detailed study & analysis are done which covers the following tests.
- Identification by 1H-NMR
- Identification by FT-IR
- Inherent viscosity (IV)
- Monomer ratio by NMR study
- End group identification by 13C NM
- Block length identification by 13C NMR
- Water content by Karl Fischer
- Glass transition temperature (Tg) by DSC
- Free acid content by a titrimetric analysis
- Residual monomer content by 1H-NMR
- Bioburden test (total aerobes, spores, and anaerobes)